or
Remember me
Back
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model
Vivos’ DNA appliance now approved to reduce snoring and treat moderate to severe OSA in children aged 6 to 17
LITTLETON, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of proprietary treatments for sleep related breathing disorders (SRBDs), including obstructive sleep apnea (OSA), today announced receipt of what is believed to be the first ever U.S. Food and Drug Administration (FDA) 510(k) clearance to treat moderate to severe OSA and snoring in children using Vivos’ proprietary flagship oral medical device. But I would have to say that this is the main reason for todays activity is A good ol "Pre-funded Warrant" dumping on the unsuspecting Chasers....read this ; ) sec.gov/Archives/edgar/data/1716166/000149315224030832/form424b1.htm
Receive investor kits and email updates from Stockhouse and directly from these companies.